Dalkon Shield: Device Injuries, Company Conduct, and Oversight

The claim and its context

The Dalkon Shield intrauterine device was associated with pelvic infections, pregnancy complications, and injuries, followed by extensive litigation and bankruptcy proceedings. The device and company response drew justified scrutiny. That history does not establish that all IUDs share the same design or risk.

Historical chronology

A.H. Robins marketed the Dalkon Shield beginning in 1971. Reports of pelvic inflammatory disease and septic pregnancy emerged; the device was withdrawn from sale in the United States in 1974. Litigation continued for years, and the manufacturer entered bankruptcy in 1985, leading to a claims trust.

What the record establishes

Clinical reports and litigation records describe serious injuries, including infection and pregnancy-related harm. The device’s multifilament tail string was implicated as a possible pathway for bacteria, though causal details varied among cases. Contemporary coverage and company records became evidence in disputes over what was known and how warnings were handled.

Clinical and scientific context

An intrauterine device’s safety depends on its materials, geometry, placement, and infection risk. Dalkon Shield’s design was distinct from modern IUDs, which undergo different testing and regulatory review. Historical injury rates from one device should not be transferred to unrelated products without comparative data.

Counterevidence, uncertainty, and calibration

The large number of legal claims is not a direct measure of incidence or proof that every injury was device-caused. Records and clinical definitions differed, and allegations about executives’ knowledge were litigated in varied procedural contexts. The evidence supports substantial harm and serious oversight questions, not a general conspiracy about contraception.

What could change the assessment

Original adverse-event records, design testing, internal correspondence, and consistent clinical comparisons could further clarify risk magnitude and company knowledge over time. Product-specific, independently collected outcome data are needed to compare current devices.

Source notes and limitations

1. Roepke and Schaff — Long Tail Strings: Impact of the Dalkon Shield 40 Years Later (2014)Peer-reviewed historical and clinical review of the device’s legacy; retrospective review depends on available case records.
2. American Medical Association Journal of Ethics — FDA Device Oversight From 1906 to the PresentEthics and regulatory history explaining the Dalkon Shield’s place in U.S. device oversight; secondary source.
3. U.S. Food and Drug Administration — History of Medical Device Regulation and OversightOfficial regulatory history of federal device oversight; the Dalkon Shield controversy preceded enactment and helped shape the policy environment.